PMID- 37152047
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230509
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage 
      III non-small cell lung cancer: a retrospective study.
PG  - 1129989
LID - 10.3389/fonc.2023.1129989 [doi]
LID - 1129989
AB  - BACKGROUND: Concurrent programmed death 1 (PD-1) or programmed death ligand 1 
      (PD-L1) inhibitors with sequential chemoradiotherapy (SCRT) have been reported in 
      only a limited number of studies involving patients with unresectable stage III 
      non-small-cell lung cancer (NSCLC). A retrospective study was conducted to 
      systematically analyze the efficacy and safety of the emerging therapy among 
      Chinese patients. MATERIALS AND METHODS: We included patients with unresectable, 
      stage III NSCLC who received concurrent sintilimab with chemotherapy or 
      chemotherapy alone for 3-6 cycles, followed by radical radiotherapy at the First 
      Hospital of Jilin University from Dec 15, 2019, to Jul 15, 2022. The primary end 
      point was the objective response rate (ORR). The secondary end points included 
      progression-free survival (PFS), overall survival (OS), 12-month and 18-month PFS 
      rates, the duration of response (DoR), and safety. RESULTS: The retrospective 
      study involved 77 patients, of which 49 receiving concurrent sintilimab with SCRT 
      were assigned to cohort A, and 28 receiving SCRT alone were assigned to cohort B. 
      The ORR was significantly higher in cohort A (79.6%, 95% CI 65.7-89.8) than in 
      cohort B (35.7%, 95% CI 18.6-55.9) (p<0.001). Median PFS was significantly longer 
      in cohort A than in cohort B (NR [95% CI 21.4-NR] vs. 16.0 months [13.0-22.5]; HR 
      0.375, 95% CI 0.192-0.735; p=0.003). The PFS rates at 12 and 18 months were 84.8% 
      (95% CI 75.0-95.9) and 71.3% (95% CI 58.7-86.7) in cohort A and 75.0% (95% CI 
      60.6-92.9) and 38.3% (95% CI 23.7-61.7) in cohort B, respectively. Grade 3 or 4 
      adverse events (AEs) were reported in 19 patients (38.8%) and seven patients 
      (25.0%) in two cohorts, respectively. Grade 3 or 4 pneumonitis or immune-mediated 
      pneumonitis, radiation pneumonitis, and pneumonia occurred in five (10.2%), four 
      (8.2%), and two (4.1%) cohort A patients, and zero, two (7.1%), and two (7.1%) 
      cohort B patients, respectively. Only cohort A reported AE leading to death in 
      one (2.0%) patient (immune-mediated pneumonitis). CONCLUSION: Concurrent 
      sintilimab with SCRT resulted in a significantly better ORR and longer PFS than 
      SCRT alone, with manageable safety profiles in Chinese patients with unresectable 
      stage III NSCLC.
CI  - Copyright (c) 2023 Tang, Cong, Zheng, Chen, Liu, Gao, Zhang, Zhang and Liu.
FAU - Tang, Shi
AU  - Tang S
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Cong, Xiaofeng
AU  - Cong X
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Zheng, Dan
AU  - Zheng D
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Chen, Chen
AU  - Chen C
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Liu, Zengguang
AU  - Liu Z
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Gao, Jie
AU  - Gao J
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Zhang, Huimin
AU  - Zhang H
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Zhang, Youhao
AU  - Zhang Y
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Liu, Ziling
AU  - Liu Z
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
LA  - eng
PT  - Journal Article
DEP - 20230420
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10157220
OTO - NOTNLM
OT  - PD1/PDL1 inhibitor
OT  - chemoradiotherapy
OT  - non-small cell lung cancer
OT  - retrospective study
OT  - safety
OT  - sintilimab
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/05/08 06:41
MHDA- 2023/05/08 06:42
PMCR- 2023/01/01
CRDT- 2023/05/08 03:57
PHST- 2022/12/22 00:00 [received]
PHST- 2023/04/05 00:00 [accepted]
PHST- 2023/05/08 06:42 [medline]
PHST- 2023/05/08 06:41 [pubmed]
PHST- 2023/05/08 03:57 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1129989 [doi]
PST - epublish
SO  - Front Oncol. 2023 Apr 20;13:1129989. doi: 10.3389/fonc.2023.1129989. eCollection 
      2023.